Laura Pazzaglia
Overview
Explore the profile of Laura Pazzaglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laranga R, Pazzaglia L, Pedrini E, Sambri A, Ferrari C, Locatelli M, et al.
Lab Invest
. 2024 Jun;
104(8):102088.
PMID: 38825319
Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by high-local recurrence rate, poorly understood molecular pathogenesis, lack of specific prognostic markers, and effective targeted therapies. To gain further...
2.
Landuzzi L, Manara M, Pazzaglia L, Lollini P, Scotlandi K
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568703
Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma carrying the chromosomal translocation t(X;18), encoding the fusion transcript SS18::SSX. The fusion oncoprotein interacts with both BAF enhancer complexes and...
3.
Gonzalez-Munoz T, Di Giannatale A, Garcia-Silva S, Santos V, Sanchez-Redondo S, Savini C, et al.
Clin Cancer Res
. 2023 Jul;
29(18):3744-3758.
PMID: 37432984
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft-tissue sarcomas that lack effective treatments, underscoring the urgent need to uncover novel mediators of MPNST pathogenesis that may serve...
4.
Scotto di Carlo F, Russo S, Muyas F, Mangini M, Garribba L, Pazzaglia L, et al.
Commun Biol
. 2023 Jan;
6(1):9.
PMID: 36599901
Profilin 1-encoded by PFN1-is a small actin-binding protein with a tumour suppressive role in various adenocarcinomas and pagetic osteosarcomas. However, its contribution to tumour development is not fully understood. Using...
5.
Palmerini E, Pazzaglia L, Cevolani L, Pratelli L, Pierini M, Quattrini I, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740530
Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, is approved for GCTB. Data on serum bone turnover marker (sBTM) changes are lacking. We present...
6.
De Feo A, Pazzaglia L, Ciuffarin L, Mangiagli F, Pasello M, Simonetti E, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406534
Ewing's sarcoma (EWS), an aggressive pediatric bone and soft-tissue sarcoma, has a very stable genome with very few genetic alterations. Unlike in most cancers, the progression of EWS appears to...
7.
Culurciello R, Bosso A, Di Fabio G, Zarrelli A, Arciello A, Carella F, et al.
Toxins (Basel)
. 2021 Dec;
13(12).
PMID: 34941723
Therapeutic treatments with have a long-established tradition in various diseases due to its antibacterial, antioxidant, antiviral, anti-malaria and anti-cancer effects. However, in relation to the latter, virtually all reports focused...
8.
Bianchi G, Lana D, Gambarotti M, Ferrari C, Sbaraglia M, Pedrini E, et al.
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34069378
Primary solitary fibrous tumor (SFT) of the bone is extremely rare, with only few cases reported in the literature. We retrieved all cases of primary SFT of the bone treated...
9.
Leonardi L, Scotlandi K, Pettinari I, Benassi M, Porcellato I, Pazzaglia L
Cells
. 2021 Mar;
10(2).
PMID: 33670554
Osteosarcoma (OS) is the most frequent primary malignant tumor of bone in humans and animals. Comparative oncology is a field of study that examines the cancer risk and tumor progression...
10.
Leonardi L, Benassi M, Pollino S, Locaputo C, Pazzaglia L
Vet Rec Open
. 2020 Mar;
7(1):e000379.
PMID: 32201579
Background: Osteosarcoma (OS) is the most common primary malignant bone tumour in dogs and human beings, characterised by similar genetic and clinical features. With the aim to define similarities and...